Physician profile
Amy E Carter
NPI 1063464501
$9,011.90
in general payments reported to CMS, 2019-2025
34 companies · $767 in 2025
The $767 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,155 · 2020: $1,601 · 2021: $1,844 · 2022: $1,529 · 2023: $1,228 · 2024: $888 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,882.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,158.10 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $844.75 | 2019-2025 | |
| Lilly USA, LLC | $777.38 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Glaxosmithkline, LLC. | $696.31 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $575.00 | 2019-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.49 | 2020-2025 | Jardiance, Trijardy Xr, Synjardy |
| Amgen INC. | $310.14 | 2019-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $297.11 | 2021-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $289.05 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $278.22 | 2019-2021 | |
| Lundbeck LLC | $273.28 | 2022-2025 | Vyepti |
| Allergan, INC. | $255.35 | 2019-2020 | |
| Abbvie INC. | $249.83 | 2021-2025 | Vraylar |
| Phathom Pharmaceuticals, INC. | $233.04 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $199.42 | 2022-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $180.77 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $166.49 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $149.28 | 2022 | |
| Abbott Laboratories | $136.46 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Eisai INC. | $128.75 | 2020-2021 | |
| Esperion Therapeutics, INC. | $83.86 | 2021-2025 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $61.83 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $59.57 | 2019-2023 | Livalo |
| Idorsia Pharmaceuticals US INC | $57.40 | 2022-2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $53.04 | 2019-2022 | |
| Philips North America LLC | $31.42 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Bioventus LLC | $23.14 | 2019 | |
| Ibsa Pharma INC. | $17.93 | 2023 | Tirosint, Licart |
| Hologic Sales and Service, LLC | $17.06 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.90 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.71 | 2020 | |
| Depuy Synthes Sales INC. | $15.38 | 2023 | Monovisc |
| Axsome Therapeutics, INC. | $15.28 | 2025 | Auvelity |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.